A share price of Xenon Pharmaceuticals Inc [XENE] is currently trading at $42.73, up 5.51%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The XENE shares have gain 6.80% over the last week, with a monthly amount drifted -0.74%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Xenon Pharmaceuticals Inc [NASDAQ: XENE] stock has seen the most recent analyst activity on January 04, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $62. Previously, Robert W. Baird started tracking the stock with Outperform rating on December 08, 2023, and set its price target to $63. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $58 on April 25, 2023. Goldman initiated its recommendation with a Buy and recommended $60 as its price target on December 14, 2022. In a note dated November 28, 2022, Wells Fargo initiated an Overweight rating and provided a target price of $50 on this stock.
Xenon Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $27.99 and $50.99. Currently, Wall Street analysts expect the stock to reach $49.14 within the next 12 months. Xenon Pharmaceuticals Inc [NASDAQ: XENE] shares were valued at $42.73 at the most recent close of the market. An investor can expect a potential return of 15.0% based on the average XENE price forecast.
Analyzing the XENE fundamentals
Gross Profit Margin for this corporation currently stands at 0.34% with Operating Profit Margin at -39.79%, Pretax Profit Margin comes in at -33.96%, and Net Profit Margin reading is -33.9%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.25 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.28 points at the first support level, and at 39.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.50, and for the 2nd resistance point, it is at 44.27.
Xenon Pharmaceuticals Inc [XENE] reported earnings per share of -$0.64 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.76/share, meaning a difference of $0.12 and a surprise factor of 15.80%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$0.73 per share as compared to estimates of -$0.77 per share, a difference of $0.04 representing a surprise of 5.20%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Xenon Pharmaceuticals Inc [NASDAQ:XENE] is 23.65. As well, the Quick Ratio is 23.65, while the Cash Ratio is 5.45.
Transactions by insiders
Recent insider trading involved GAROFALO ELIZABETH A., Director, that happened on Mar 08 ’24 when 2092.0 shares were sold. Director, GANNON STEVEN completed a deal on Mar 07 ’24 to sell 13000.0 shares. Meanwhile, EVP, Strategy & Innovation ROBIN SHERRINGTON sold 7137.0 shares on Mar 07 ’24.
